Sandra Sauer

Dec 4, 2024 | nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more

AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.

Mar 13, 2024 | nature.com | Sandra Sauer |Monika Engelhardt

AbstractThere are limited data guiding choice of re-induction therapies for patients with relapsed/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of 171 patients with RRMM in Germany who received re-induction therapy in second line (78%; n = 134) or third line (22%; n = 37) prior to re-SCT.